Health developments span treatment advances for cancer and autoimmune diseases, diagnostic innovations for breast cancer risk, and emerging questions about Alzheimer's therapy effectiveness, while workforce challenges in global disease response efforts continue.

Ebola response workers in northeastern Democratic Republic of Congo protested outside treatment centers Thursday, claiming they have not received full payment for their work, highlighting ongoing challenges in global health response funding and worker compensation.

Polatuzumab vedotin combined with R-GemOx demonstrated improved survival outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem cell transplants, offering a new treatment option for this patient population.

MRI imaging showing higher background parenchymal enhancement can predict increased breast cancer risk in women carrying BRCA mutations, potentially improving personalized screening approaches for high-risk individuals.

Researchers debate whether antiamyloid Alzheimer's drugs, which clear amyloid plaques and modestly slow cognitive decline, deliver meaningful clinical benefits—raising questions about current treatment paradigms and research priorities in neurodegenerative disease.

JAK inhibitors in systemic sclerosis patients show effectiveness comparable to standard immunosuppressants, though many patients discontinue treatment due to efficacy failures or adverse events, indicating need for better tolerability profiles.

Structured predialysis education programs help chronic kidney disease patients in stages 4 and 5 choose peritoneal dialysis over hemodialysis, suggesting patient education can influence treatment selection and outcomes.

Abrocitinib achieves minimal disease activity in atopic dermatitis patients regardless of prior dupilumab exposure, expanding treatment options for patients with moderate-to-severe eczema.

A 10-week study found no connection between hypoglycemic episodes and depression, anxiety, diabetes distress, or condition-related fear in adults with type 1 and insulin-treated type 2 diabetes, challenging assumptions about glucose fluctuations and mental health links.